PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.

@article{Kirschner2015PIMKI,
  title={PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.},
  author={Austin N. Kirschner and Jie Wang and Riet van der Meer and Philip D. Anderson and Omar E Franco-Coronel and Max H Kushner and Joel H Everett and O. M. Abd El Hameed and Erika Krasnickas Keeton and Miika J Ahdesmaki and Shaun E. Grosskurth and Dennis Huszar and Sarki A. Abdulkadir},
  journal={Journal of the National Cancer Institute},
  year={2015},
  volume={107 2}
}
BACKGROUND PIM1 kinase is coexpressed with c-MYC in human prostate cancers (PCs) and dramatically enhances c-MYC-induced tumorigenicity. Here we examine the effects of a novel oral PIM inhibitor, AZD1208, on prostate tumorigenesis and recurrence. METHODS A mouse c-MYC/Pim1-transduced tissue recombination PC model, Myc-CaP allografts, and human PC xenografts were treated with AZD1208 (n = 5-11 per group). Androgen-sensitive and castrate-resistant prostate cancer (CRPC) models were studied as… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Efficacy and biomarker modulation by AZD1208, a novel, potent and selective pan-Pim kinase inhibitor, in models of acute myeloid leukemia

  • E Keeton, K McEachern, M Alimzhanov
  • Proceedings of the 103rd Annual Meeting of the…
  • 2012

AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia

  • E Keeton, S Palakurthi, M Alimzhanov
  • ASH Annual Meeting Abstracts
  • 2011

Similar Papers

Loading similar papers…